Source link : https://www.newshealth.biz/health-news/filgotinib-cuts-treatment-failures-in-uveitis/
TOPLINE: Filgotinib, a Janus kinase 1 inhibitor, was well tolerated and reduced treatment failures in patients with active noninfectious uveitis in a phase 2 randomized trial despite early termination of the study. METHODOLOGY: HUMBOLDT, a phase 2, randomized clinical trial, was conducted at 26 centers across seven countries to assess the efficacy and safety of […]
Author : News Health
Publish date : 2024-07-19 10:10:18
Copyright for syndicated content belongs to the linked Source.